Interleukin-2 does not sequester activated lymphocytes into lung lymph of sheep

The Journal of Surgical Research
D M MahviF K Storm

Abstract

Interleukin-2 (IL-2) is a potent activator of lymphocytes, but its effectiveness as an anti-cancer agent is compromised by several adverse side effects including pulmonary edema. One explanation for the pulmonary toxicity of IL-2 is that activated lymphocytes directly induce the pulmonary vascular endothelium to become more leaky. To test this hypothesis the number of total lymphocytes, gamma delta T cells, and CD2-positive cells (alpha beta T cells and natural killer cells) in peripheral blood and lung lymph of sheep were compared before and after IL-2 infusion. Hemodynamic and lymph dynamic changes were also evaluated. IL-2 decreased mean aortic pressure, increased cardiac output, lowered systemic vascular resistance, and doubled lung lymph flow (P < or = 0.05), but had no effect on plasma or lymph oncotic pressure. The lymph protein concentration and the lymph-to-plasma protein concentration ratio were not different after IL-2 infusion. IL-2 had no effect on the number of total lymphocytes, gamma delta T cells, or CD2-positive cells in the peripheral blood. In contrast, the number of total lymphocytes, gamma delta T cells, and CD2-positive cells in lung lymph decreased significantly (P < or = 0.05). The lymphocyte population...Continue Reading

Related Concepts

Related Feeds

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

Related Papers

APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica
Dai Fukumura, Rakesh K Jain
Pediatrics International : Official Journal of the Japan Pediatric Society
Masami MizobuchiHideto Nakao
Journal of Controlled Release : Official Journal of the Controlled Release Society
Fabienne DanhierVéronique Préat
© 2021 Meta ULC. All rights reserved